Welcome to
Elusys Therapeutics, Inc.

Elusys is a private, commercial-stage biopharmaceutical company that has achieved US and international licensure in Canada, the UK, and the EU for its lead antibody therapeutic, a medical countermeasure to treat patients following anthrax exposure after a natural or intentional terrorist incident.

B. Anthracis Rods


  • Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of   Inhalational Anthrax Under the US FDA Animal Rule
  • Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity
  • Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre-and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax